To the Editor: We read with interest the case report describing the development of hidradenitis suppurativa (HS) lesions after radiation treatment in a patient with uterine adenocarcinoma.1 The authors provided several thoughts on the possible mechanism behind radiation-induced HS. The purpose of this letter is to provide additional insight about the likely immunologic mechanisms behind radiation-induced HS. The reported case is an example of an abscopal-like effect2 sharing adenocarcinoma antigens to antigens of apocrine glands of the groin. Abscopal effect is an immune-mediated phenomenon that has been heavily discussed in metastatic melanoma, whereby there is regression of nonirradiated metastatic lesions after irradiation of a distant melanoma tumor location.3, 4 Abscopal effects were also recently reported in advanced melanoma patients after immunotherapy, highlighting the therapeutic implications of this phenomenon.5
As the authors point out, apoptosis can be induced by irradiation.1 It is likely that apoptotic uterine adenocarcinoma cells result in T-cell cross priming after radiation6 and activate Th17 subset. A recent article points out that Th17 is an important subset in the immunopathogenesis of HS,7, 8 like it is in psoriasis.9 This case and the article by Matusiak et al7 make a strong case that HS, like psoriasis, is an autoimmune disease with Th17 and the attendant polymorphonuclear leukocytes involved. Oppman et al10 identified the p19 third subunit of interleukin (IL)-12, and designated it as IL-23. This finding predicted the potential for treating psoriasis with anti–IL-12 ustekinumab and anti–IL-23 (guselkumab). This case of radiation-induced HS is likely to predict a positive outcome with clinical trials for HS with ustekinumab (IL-12 antagonist),11 secukinumab (IL-17 antagonist),12 and guselkumab (IL-23 antagonist).13
Footnotes
Funding sources: None.
Conflicts of interest: None declared.
References
- 1.Haber R., Gottlieb J., Zagdanski A., Battistella M., Bachelez H. Radiation-induced hidradenitis suppurativa: a case report. JAAD Case Rep. 2017;3(3):182–184. doi: 10.1016/j.jdcr.2017.02.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Postow M.A., Callahan M.K., Barker C.A. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–931. doi: 10.1056/NEJMoa1112824. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Espenel S., Vallard A., Rancoule C. Melanoma: last call for radiotherapy. Crit Rev Oncol. 2017;110:13–19. doi: 10.1016/j.critrevonc.2016.12.003. [DOI] [PubMed] [Google Scholar]
- 4.Dany M. Sphingosine metabolism as a therapeutic target in cutaneous melanoma. Translational Res. 2017;185:1–12. doi: 10.1016/j.trsl.2017.04.005. [DOI] [PubMed] [Google Scholar]
- 5.Sharabi A.B., Lim M., DeWeese T.L., Drake C.G. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498–509. doi: 10.1016/S1470-2045(15)00007-8. [DOI] [PubMed] [Google Scholar]
- 6.Morisada M., Moore E.C., Hodge R. Dose-dependent enhancement of T-lymphocyte priming and CTL lysis following ionizing radiation in an engineered model of oral cancer. Oral Oncol. 2017;71:87–94. doi: 10.1016/j.oraloncology.2017.06.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Matusiak Ł., Szczęch J., Bieniek A., Nowicka-Suszko D., Szepietowski J.C. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76(4):670–675. doi: 10.1016/j.jaad.2016.10.042. [DOI] [PubMed] [Google Scholar]
- 8.Dany M., Elston D. Gene expression of sphingolipid metabolism pathways is altered in hidradenitis suppurativa. J Am Acad Dermatol. 2017;77(2):268–273.e6. doi: 10.1016/j.jaad.2017.03.016. [DOI] [PubMed] [Google Scholar]
- 9.Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350. doi: 10.1038/jid.2009.59. [DOI] [PubMed] [Google Scholar]
- 10.Oppmann B., Lesley R., Blom B. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–725. doi: 10.1016/s1074-7613(00)00070-4. [DOI] [PubMed] [Google Scholar]
- 11.Leonardi C.L., Kimball A.B., Papp K.A. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet. 2008;371(9625):1665–1674. doi: 10.1016/S0140-6736(08)60725-4. [DOI] [PubMed] [Google Scholar]
- 12.McInnes I.B., Mease P.J., Kirkham B. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146. doi: 10.1016/S0140-6736(15)61134-5. [DOI] [PubMed] [Google Scholar]
- 13.Sofen H., Smith S., Matheson R.T. Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–1040. doi: 10.1016/j.jaci.2014.01.025. [DOI] [PubMed] [Google Scholar]